Skip to content

Autonomic Nervous Activity in Women With Gestational Diabetes

Autonomic Nervous Activity in Women With Gestational Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00867022
Enrollment
80
Registered
2009-03-23
Start date
2004-08-31
Completion date
2009-03-31
Last updated
2009-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

Inflammatory factors, Coagulation factors, Sympathetic activity

Brief summary

Through complex hormonal pathways, insulin resistance can lead to the activation of the sympathetic nervous system, and vice versa. Schobel et al. showed that in PE patients, mus-cle sympathetic nerve activity (MSNA) is increased compared with normotensive pregnant and non-pregnant women. Studies assessing heart-rate variability and plasma noradrenalin concentrations also suggest increased sympathetic activity in PE. It has been hypothesized that sympathetic over-activity is a precursor of PE, normally compensated for by vasodilating mechanisms, but resulting in PE when the mechanisms fail. In addition to sympathetic activity, various markers of inflamma-tion are also associated with reduced insulin sensitivity, suggesting that chronic sub-clinical inflamma-tion could be part of the insulin resistance syndrome. The role of sympathetic over-activity and inflammatory markers in gestational diabetes has not been investigated

Interventions

None listed

Sponsors

University of Helsinki
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of gestational diabetes (OGTT) with or without BP \> 140/90. * Pregnant control with normal OGTT-

Exclusion criteria

* Smoking * Uncontrolled hypertension * Diabetes * Medication affecting sympathetic activity

Design outcomes

Primary

MeasureTime frame
Serum Noradrenalin level

Secondary

MeasureTime frame
Heart rate variability: LF, VLF, HF

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026